drugset / Trial / NCT00220857
Rabeprazole Protection of Aspirin Induced Gastric Damage.
RandomizedParallel-groupDouble-blindPrevention
Summary
To determine the effectiveness of rabeprazole in preventing or decreasing acute gastroduodenal injury caused by therapeutic doses of aspirin in a placebo-controlled, randomized, double-blind parallel group study.
Timeline
- Start
- 2005-09
- Primary completion
- 2007-09
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rabeprazole | Small molecule | 20 mg | Oral |
Indications
No indication recorded.